Clarius Wins FDA Clearance for AI Cardiac Ultrasound Tool
VANCOUVER, British Columbia, June 2, 2026 Clarius Mobile Health has achieved a significant regulatory milestone with the U.S. Food...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
VANCOUVER, British Columbia, June 2, 2026 Clarius Mobile Health has achieved a significant regulatory milestone with the U.S. Food...
CHARLOTTESVILLE, Va., May 7, 2026 RIVANNA announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...
VANCOUVER, BC, Dec. 17, 2025 — Clarius Mobile Health, a global leader in AI-powered handheld ultrasound technology, reported a...
